Company Overview and News

GBP/USD - Pound Slide Continues As U.S. Nonfarm Payrolls Beats Expectations

2017-08-04 seekingalpha
GBP/USD has posted losses in the Friday session, continuing the downward trend seen on Thursday. In the North American session, the pair is trading at the 1.31 line, down 0.24% on the day. On the release front, there are no British events on the schedule. In the US, employment numbers were solid. Nonfarm payrolls slowed to 209 thousand, but easily beat the estimate of 182 thousand. Wage growth remained steady at 0.
Upvote Downvote

EUR/USD - Euro In Holding Pattern Ahead Of US Nonfarm Payrolls

2017-08-04 seekingalpha
EUR/USD has inched higher in the Friday session. Currently, the pair is trading at 1.1880, up 0.10% on the day. On the release front, German Factory Orders climbed 1.0%, beating the estimate of 0.6%. Eurozone Retail PMI slowed to 51.0, marking a 4-month low. In the US, the focus will be on employment data. Nonfarm Payrolls is expected to slow to 182 thousand, while wage growth is forecast to edge up to 0.
Upvote Downvote

USD/CAD - Canadian Dollar Steady Ahead Of U.S., Canadian Job Reports

2017-08-04 seekingalpha
The Canadian dollar continues to trade quietly, as USD/CAD has inched lower in the Friday session. Currently, the pair is trading at 1.2570, down 0.10% on the day. Canada and the US will both release key employment numbers in the North American session, so traders should be prepared for movement from the pair. In the US, Nonfarm Payrolls is expected to slow to 182 thousand, while wage growth is forecast to edge up to 0.
Upvote Downvote

Australian Army Ground-Based Air Defence Capability

2016-08-16 asdnews
Defence and security company Saab has signed a contract with the Australian Defence Force to upgrade the Army’s RBS 70 ground-based air defence weapon system and Giraffe AMB radar. The contract has a combined value of approximately AUD32.5 million.
Upvote Downvote

International Flavors And Fragrances: Passing The Smell Test In '16

2016-01-25 seekingalpha
IFF's outperformance of the S&P 500 Index seems to have paused, as analysts trim their estimates.Inchoate worries about currencies and emerging markets seem to
Upvote Downvote

Dividend Contenders: Better Choice Than Dividend Aristocrats?

2016-01-24 seekingalpha
Dividend Contenders have raised dividends for 10-24 years consecutively.These companies are the future stars of the dividend investing world.However, have their
Upvote Downvote

International Flavors & Fragrances' Prospects Hurt by Risks

2016-01-18 zacks
We issued an updated research report on International Flavors & Fragrances Inc. (IFF) on Jan 15, 2016.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...